We were also joined by Leader of Stockport Borough Council Councillor Mark Hunter, Immediate Past Mayor of Stockport Councillor Graham Greenhalgh, Deputy Lieutenants Mr Paul Brearley JP, Mr Gerry Yeung OBE and Rev Charles Kwaku-Odoi, who all joined us to celebrate our achievement of being Stockport’s only recipient of the King’s Award for Enterprise 2024.

During the reception, we discussed Seda’s exceptional growth, future growth potential through our investment and expansion into GMP manufacturing, our rapidly expanding global Client portfolio and the positive impact this is having on the local economy and our ability to create new, high-skilled jobs in the region.

A special thank you to Madam Mayor Suzanne for hosting this wonderful event and for the opportunity to connect with the other Council leaders and Deputy Lieutenants.

We welcome the opportunity to continue this collaboration with our local community leaders to drive positive change into the Stockport eco-system.

About King’s Awards for Enterprise
The King’s Awards for Enterprise are the most prestigious business awards in the UK. The awards were first established in 1965 and since then over 7000 companies have achieved a King’s Award. 2024 marks the second year of The King’s Awards for Enterprise, reflecting His Majesty The King’s desire to continue the legacy of HM Queen Elizabeth II’s by recognising outstanding UK businesses.

The awards celebrate the success of exciting and innovative businesses which are leading the way with pioneering products or services, delivering impressive social mobility programmes, or showing their commitment to excellent sustainable development practices.

This year 252 businesses have been recognised for their contribution to International Trade, Innovation, Sustainable Development and Promoting Opportunity (through Social Mobility). A total of 257 Awards are made with five companies being recognised with two Awards.

The King’s Awards for Enterprise 2024 include:
• 161 Awards for International Trade
• 59 Awards for Innovation
• 29 Awards for Sustainable Development
• 8 Awards for Promoting Opportunity (through social mobility)

Congratulations to our fellow Kings Award winners. Click here for the full list.

The post Seda attend a Civic Reception to celebrate King’s Award win appeared first on Seda.

On our stand #80M10 will be Marcel de Matas (Chief Technology Officer & Co-Founder), Shanoo Budhdeo (Director: Pharmaceutical Sciences), Paula Goddard (Head of Sales and Marketing) and Effi Baetzner (Principal Scientist). CPHI creates connections and inspires partnerships across the global pharma community. It attracts around 45,000 visiting pharma professionals and 2,500+ exhibitors from more than 150 countries, thus providing a unique opportunity for Seda to interface with many potential customers in one area. 

Since recently being awarded Life Science Innovator Category Winner 2023 in the Application, Product & Service Design Category, we have been working closely with the Department for Business and Trade and are delighted to have been invited to have our own stand #80M10 on the UK pavilion.

At Seda we endeavour to maximise value through integrated Pharmaceutical Development and Clinical Pharmacology support. We enable rapid and efficient development of optimal medicinal products, from conventional to complex, through pragmatic and coherent scientific excellence. Come to see us at our stand to find out more about the services we provide and how we can support your development program. 

If you will be attending CPHI Barcelona 2023 and would like to set up a meeting with one of our team, please contact us here. 

The post Seda are Exhibiting – CPHI Barcelona 2023 appeared first on Seda.

On Tuesday 8th November 2022, Seda hosted an Open Day at our new state-of-the-art Head Quarters based at Cheadle Royal Business Park. There was a great turn out for our first event, with more than 40 guests from all over the UK. It was a brilliant opportunity to welcome our existing clients and business partners and for our new contacts to see where the magic happens! 

The Open Day showcased our new facilities alongside demonstrations of the services that we offer. In particular, the Open Day launched Seda’s new in-silico offering MI-DAS (Model-Informed Development of Amorphous Systems), state of the art processing suites, and our capabilities surrounding the design and development of complex medicines. 

The day began with a welcome and introduction from Seda’s directors, with Paul Stott presenting an overview of Seda’s history and a glimpse into our future direction. Paul Dickinson offered some insight into Seda’s integrated modelling capabilities, and how this supports all stages of the drug development process, followed by Marcel de Matas introducing Seda’s laboratory offerings. Our guests got first-hand demonstrations of our laboratory capabilities during the lab tours, with Seda’s analytical, formulation, dissolution and processing equipment in action. The day finished with a delicious lunch provided by Open Kitchen MCR.

There were a lot of inspiring scientific discussions and networking during the poster session – it was great to meet some new contacts and also see some familiar faces! 

If you were unable to attend the Open Day but would be interested in seeing our facilities at another time or would like to set up a meeting to find out more about the services we can provide, please don’t hesitate to contact us. 

Photos taken by Decoy Media. 

The post Seda hosts Open Day appeared first on Seda.

Senior Principal Scientist, Claire Patterson and Senior Modeller, Jake Dickinson will be presenting in the rapid-fire sessions. Claire will present ‘It’s never too early to put the patient first’ on Wednesday 19th October at 3:15pm-3:30pm EST, discussing the importance of early consideration of patient centric product design particularly for complex products such as nanomedicines and long-acting injectables.

Jake’s rapid-fire presentation ‘Streamlined pathways to clinical success through integrated modelling in model informed drug development (MIDD)’ is taking place in the ‘Role in Dose Selection, Vulnerable Populations, and Biowaivers’ session on Tuesday 18th October 3:30pm-3:45pm EST. Jake will discuss how integrated modelling can provide streamlined pathways to clinical success through dose-selection and alternative routes of determining bioequivalence.   

Jake also has a poster presentation on Wednesday 19th October 2:30pm-3:30pm EST, titled ‘Setting up success in the clinic through semi-mechanistic translational modelling’. Demonstrating a novel data-driven approach combining early preclinical and available clinical data to predict clinical Objective Response Rate (ORR) which can be used to support dosing decisions and make early evaluations of candidate drugs. 

Jake and Claire will be accompanied by Seda senior executives Paul Stott, Paul Dickinson and Marcel de Matas, as well as Modeller Harri Dickinson.

We are looking forward to exhibiting at AAPS PharmSci 360 2022 and see it as a great opportunity to showcase our services to the North American market especially in the Boston area. We also hope to reconnect with our US-based friends and colleagues, and to further expand our international network. If you are in the area or attending the conference and wish to meet with us, please contact us to arrange a time, or drop by at booth #1436. We can’t wait to see you!  

The post AAPS PharmSci 360 2022 – Seda on Tour! appeared first on Seda.

Seda Pharmaceutical Development Services are delighted to announce an Open Day on Tuesday 8th November 2022 to celebrate the opening of our new HQ at Cheadle Royal Business Park in Greater Manchester. This Open Day is perfect for anyone wishing to learn about Seda, tour our facilities and meet the Seda team in person.   

The Open Day will showcase Seda and the services we offer; from drug product consulting and pharmacokinetic modelling through to laboratory-based drug product development and small scale (non-GMP) product manufacture.  

Throughout the day there will be tours of the laboratory and product processing areas, demonstrations of our capabilities, and opportunities for networking with our colleagues and other delegates. Opportunities for 1-2-1 interactions with specific team members are also available on request. 

Lunch and refreshments will be provided. 

If you would like to find out more about the event or request tickets, please enter your details in the form below and a member of the Seda team will be in touch. 

Seda was founded in 2015 by pharmaceutical experts Paul Dickinson and Marcel de Matas to provide consultancy services across the biotech industry, originally based at Alderley Park. 

The decision to change location was driven by the recent period of rapid growth within the company, with ambitious plans for further expansion over the coming years, both in terms of personnel and in the services we offer to our clients.    

Seda has undertaken a full refit of the new property, with a total investment nearing £4m, developing state-of-the-art laboratories and bespoke office space. This is enabling us to invest in new equipment to expand the range of services we offer clients.   

We look forward to welcoming you to our new home. 

The post Seda announces Open Day appeared first on Seda.

Some key messages from Claire’s presentation:

• The First step in formulation design is the target product profile (TPP) which brings together patient, disease, and molecule factors for optimal performance.
• Implicit in the TPP is selection of optimal route of administration
• Apply biopharma ceutics thinking – understand the physicochemical properties, administration site physiology and their interaction to achieve target in vivo performance profile.
• Understand the competing processes and use mathematical modelling to understand limitations and mitigations.  This is a key Seda capability.
• Understanding the rate limiting step in absorption to enable selection of appropriate formulation mitigation strategy, e.g. amorphous solid dispersions for solubility limited absorption. Where other factors limit bioavilability e.g instability, low inherent permeability/extensive efflux, extensive gut wall or hepatic first pass metabolism explore other options such as permeation enhancers or targeting ligands, or consider parenteral administration.
• There is an increasing trend towards subcutaneous delivery in oncology, particularly mAbs. Clear advantages over IV, not least the ability for the patients to self administer or at least require much less hospital/ chair time than IV infusion.
• Mechanistic understanding of absorption rate and bioavailability is lagging behind that for oral, but significant progress is being made and Seda are linked in to communities driving these developments.

The Bionow conference will also feature other insightful discussions and presentations including Early Detection/New Approaches, Multiomics in Oncology Research, Role of Biobanks in Cancer Research & Patient Care – Benchtop to Bedside, The Use of Wearables and AI to get Close to Patients and The Future of Cancer Therapy. Other keynote speakers at the event include Anke Bruning Richardson, University of Huddersfield and Kimberly Shepard, Lonza. 

As a gold exhibitor, we will also have a stand in the exhibition to promote our capabilities. Come and see us to find out more about our complex medicines expertise and how we can provide value to your business. 

The post Bionow – 2021 Oncology Conference appeared first on Seda.

Please see the flyer for further details on this and future webinars in the series.

The webinar series is brought to you by experts from the Pharmaceutical Industry and representatives from global Regulatory Agencies. It will be of relevance to Industry, Regulators, specialist technology providers, Private Sector and Academic colleagues. The aim is to share and discuss progress and challenges through scientific presentations and Q&A sessions. The webinars will cover the current state of scientific affairs in the field, emerging trends and identify areas where Industry and Regulators can engage to further harmonise and enable CRDS development moving forwards.

“I believe that clinically relevant specifications are good for patients, regulators and medicines manufacturers alike, so I am very happy to support this seminar series and grateful to the organising committee for their hard work and dedication to make it happen. This is a great opportunity to learn about this topic that is so important for successful drug product development” – Paul Dickinson

The webinar is free to Academy of Pharmaceutical Sciences members, or £60 for non-members. Visit  APS Events for registration.

The post Paul Dickinson Presents: Developing Clinically Relevant Dissolution Specifications in APS Virtual Webinar Series appeared first on Seda.